The goal of this observational study is to confirm the safety and efficacy of the Hexanium TLIF system in the treatment of skeletally mature patients suffering from degenerative disc disease (disease that occurs when the spinal disk break down).
Part of their standard of care, participants will be questioned on their back and leg pains, their disability and if they have encountered any adverse effects since the Hexanium TLIF system implant surgery. Those data will be collected up to twenty four (24) months after the Hexanium TLIF system implant surgery.
Patient planned for Hexanium TLIF system implant or patient implant with Hexanium TLIF system (not prior to July 2021)
Patient of 18 years old or more
Patient has provided signed informed consent, or did not oppose to his/her data collection, per local regulation
Infection, local to the operative site
Signed of local inflammation
Fever or leukocytosis
Morbid obesity
SPINEVISION SAS
Lead sponsor
EVAMED
Collaborator